View Older Stories View More Recent Stories

Apr 11, 2023 07:00AM Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
Mar 28, 2023 05:52AM Athira Pharma (ATHA) Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton
Mar 28, 2023 01:00AM Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
Mar 28, 2023 01:00AM Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
Mar 23, 2023 04:05PM Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
Mar 23, 2023 04:05PM Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
Mar 8, 2023 07:00AM Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
Mar 8, 2023 07:00AM Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
Dec 21, 2022 07:00AM Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
Dec 21, 2022 07:00AM Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
Dec 5, 2022 07:30AM Athira Pharma Inc. (ATHA) Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
Dec 5, 2022 07:30AM Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
Dec 5, 2022 07:30AM Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
Dec 1, 2022 07:00AM Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
Dec 1, 2022 07:00AM Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
Nov 29, 2022 11:01AM Athira Pharma. (ATHA) Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD
Nov 29, 2022 11:00AM Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Confere
Nov 29, 2022 11:00AM Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Confere
Nov 28, 2022 07:00AM Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
Nov 28, 2022 07:00AM Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
Nov 21, 2022 07:00AM Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Nov 21, 2022 07:00AM Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Nov 16, 2022 07:00AM Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
Nov 16, 2022 07:00AM Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
Nov 10, 2022 04:05PM Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Nov 10, 2022 04:05PM Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Nov 9, 2022 07:00AM Athira Pharma to Present at Stifel 2022 Healthcare Conference
Nov 7, 2022 07:00AM Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
Nov 7, 2022 07:00AM Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
Oct 17, 2022 07:02AM Athira Pharma Inc. (ATHA) Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Oct 17, 2022 07:00AM Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
Oct 17, 2022 07:00AM Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
Sep 6, 2022 07:03AM Athira Pharma (ATHA) Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Sep 6, 2022 07:00AM Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Sep 6, 2022 07:00AM Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Aug 15, 2022 04:05PM Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Aug 15, 2022 04:05PM Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Aug 3, 2022 11:29AM Athira Pharma (ATHA) Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Aug 3, 2022 11:28AM Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022
Aug 3, 2022 11:28AM Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference
Aug 2, 2022 03:31PM Athira Pharma (ATHA) Presents Preclinical Data at the Alzheimer's Association International Conference 2022
Aug 2, 2022 03:30PM Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
Aug 2, 2022 03:30PM Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
Jul 25, 2022 07:00AM Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022
Jul 25, 2022 07:00AM Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022
Jun 22, 2022 07:01AM Athira Pharma (ATHA) Reports Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton
Jun 22, 2022 07:00AM Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Jun 22, 2022 07:00AM Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Jun 7, 2022 07:00AM Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
Jun 7, 2022 07:00AM Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
View More Recent Stories View Older Stories